VSL#3 administration protected against the development of wasting disease measured by the weight loss and the diarrhea score (Figure 1A and 1B; n = 8–10, #p<0.05 versus naive group; *p<0.05 versus TNBS group) and reduced the macroscopic score of colitis (Figure 1 C; #p<0.05 versus control group; *p<0.05 versus TNBS group); moreover, it attenuated colon neutrophils infiltration, as measured by assessing the colonic activity of MPO (Figure 1 D #p<0.05 versus naive group; *p<0.05 versus TNBS group). This evidence concerns the gene MPO and colitis.